Retrospective study of trifluridine/tipiracil hydrochloride plus bevacizumab for vulnerable patients with previously treated metastatic colorectal cancer(WJOG14520G)
Latest Information Update: 27 Feb 2023
At a glance
- Drugs Bevacizumab (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms TWILIGHT
- 21 Jan 2023 Results (n=93) presented at the 2023 Gastrointestinal Cancers Symposium
- 10 Jan 2023 Status changed from active, no longer recruiting to completed.
- 01 Mar 2022 Status changed from recruiting to active, no longer recruiting.